Introduction {#s1}
============

Dendritic cells (DCs) are specialized antigen presenting cells (APCs) in the immune system ([@B1]). DCs are central to pathogen sensing *via* an array of pathogen recognition receptors e.g., toll like receptors (TLRs) and stimulating antigen-specific T cells to proliferate and differentiate into effector and memory cells ([@B2]). Ligand binding to TLRs leads to DC activation and an enhanced capacity to stimulate T cells. DC activation is intrinsically linked to metabolic reprogramming ([@B3]). Currently, DC metabolism is mostly studied in the murine system, primarily using TLR4 agonist lipopolysaccharide (LPS) ([@B4]--[@B7]). Limited knowledge is available about the metabolic switch in human DCs ([@B8]--[@B10]). Furthermore, it is unclear whether all stimuli induce glycolysis in human DCs. In mice, TLR stimulation upregulates glycolysis, contributing to the metabolic requirements of high protein synthesis, a prerequisite for DC immune function. The TLR-stimulated "glycolytic burst" triggers *de novo* fatty acid synthesis through glucose-to-citrate metabolism, which is indispensable for DC function ([@B4], [@B5]).

Mitochondria are crucial for metabolic function. PTEN-induced putative kinase 1 (PINK1) predominantly localizes to the outer membrane of the mitochondria ([@B11], [@B12]) and is linked to mitochondrial function and subsequent metabolism ([@B13]). *PINK1* encodes a 581 amino acid protein with an N-terminal mitochondrial targeting sequence (MTS), a transmembrane domain (TMD), followed by a serine/threonine kinase domain. PINK1 is imported into mitochondria *via* the TOM or TIM23 complexes at the outer or inner mitochondrial membrane, respectively. Subsequently, its MTS is cleaved off by the mitochondrial processing peptidase located in the matrix. Afterwards, the inner mitochondrial membrane protease presenilin-associated rhomboid-like protease (PARL) cleaves PINK1 within the hydrophobic TMD between amino acids Ala103 and Phe104 ([@B14]--[@B19]). This generates 52 kDa N-terminally processed PINK1, which is released to the cytosol, where it is rapidly degraded by the proteasome through the N-end rule pathway ([@B20]). PINK1 is required for various cellular processes, e.g., regulation of mitochondrial bioenergetics through modulating complex I activity, promotion of mitophagy of depolarized mitochondria, protection against cell death, and protection of mitochondria via mitochondria-derived vesicles (MDV) ([@B21]).

Amino acids are the building blocks of proteins in mammals and their availability is of fundamental importance for cell survival, maintenance, and proliferation ([@B22]). Amino acids ([@B23]), especially glutamine ([@B24]--[@B26]), arginine ([@B27], [@B28]), and sulfur-containing amino acids ([@B29]) are of importance for the functioning of immune cells. Much less is known about the impact of branched-chain amino acids (BCAAs), valine, leucine, and isoleucine, on cells of the immune system. BCAA-transaminase converts BCAA into their corresponding branched-chain α-ketoacids (BCKAs). Then, BCKAs are catabolized by the branched-chain α-ketoacid dehydrogenase (BCKDH) complex within the mitochondrial matrix. Subsequently, acetyl-CoA is formed by metabolic reactions and incorporated into the tricarboxylic acid (TCA) cycle, or it enters the complex II of the electron transport chain ([@B30]). This process contributes to ATP production, which under physiological conditions is produced by OXPHOS. We here confirm previous results that a shift from OXPHOS to glycolysis occurs in human DCs stimulated with TLR4 agonist LPS ([@B6]). However, upon TLR7/8 stimulation of human DC we did not observe glycolysis. Instead we observed increased OXPHOS, which required FAO for immune function. These observations propose a scenario in which individual stimuli induce distinct metabolic reprogramming.

Materials and Methods {#s2}
=====================

Chemicals
---------

Antimycin A (\#A8674), Oligomycin A (\#O4876), Rotenone (\#R8875), Kinetin (\#48130), Etomoxir (\#E1905), Lipopolysaccharides from *Escherichia coli* 0111:B4 (\#L4391), and 3,6-Dichloro-benzo\[b\]thiophene-2-carboxylic acid (\#ENA018104907) were obtained from Sigma-Aldrich. MitoTracker™ Green FM (\#M7514), and 2-NBDG (\#N13195) were obtained from Thermo Fisher Scientific.

Human DC Culture and Stimulation
--------------------------------

Human monocyte-derived DCs were differentiated from peripheral blood monocytes as follows. Buffy coats were obtained from healthy volunteers (Sanquin, Nijmegen, Netherlands) according to institutional guidelines. Peripheral blood mononuclear cells (PBMCs) were isolated by using Ficoll density centrifugation (Lymphoprep; Axis-Shield PoC AS, Oslo, Norway). Monocytes were isolated from peripheral blood mononuclear cells (PBMC) by adherence, as described previously ([@B31]) and cultured in complete DC medium supplemented with human recombinant GM-CSF (20 ng/mL) plus human recombinant IL-4 (20 ng/mL) (Peprotech) for 7 days. To generate immunosuppressive DC, 10^−6^ M Dexamethasone was added at day 3 in culture. On day 6 or 7, DCs were harvested, stimulated with LPS or protamine-RNA (pRNA) complex, which was made freshly before being added to the cells. Protamine (protaminehydrochloride MPH 5000 IE/ml; Meda Pharma BV Amstelveen, Netherlands) was diluted to 0.5 mg/ml in RNase free water and mixed with 2 kbp-long single-stranded mRNA (coding for gp100). It was extensively mixed and incubated for 5--10 min at room temperature, before adding to the cells.

siRNA Transfection
------------------

For RNA interference, cells were transfected with SilencerSelect siRNA (Invitrogen), control siRNA (4390843), and siRNA targeting PINK1 (\#s35166 and \#s35168). At day 4 of the culture, the cells were harvested, washed with PBS, brought to a concentration of 1 × 10^6^ cells/100 μL resuspension buffer, and finally, transfected by electroporation with either 10 nM anti-PINK1 siRNA (\#s35166) in combination with 10 nM anti-PINK1 siRNA (\#s35168) or 20 nM control siRNA using the Neon transfection system (Invitrogen), according to the manufacturer\'s instructions. Electroporation was carried out with an electroporator (Neon with pipette station; Invitrogen) using three pulses (10 ms pulse width; 1350 V). After electroporation, cells were taken up in 10% FCS basal media without antibiotics and plated at 200 cells/μL. The next morning, the media was re-supplemented with penicillin, streptomycin, rGM-CSF, and rIL-4. At day 6, the cells were harvested, stimulated, and analyzed. Silencing efficiency was determined by western blot and qPCR of day 6 cells.

Cytokine Detection
------------------

Supernatant was taken from each sample after incubation and analyzed with standard sandwich ELISAs to detect TNF-α using human TNF-α ELISA Kit (\#88-7346-22) from Thermo Fisher Scientific.

Flow Cytometry
--------------

Cell viability was determined using Fixable Viability Dye eFluor™ 780 (Invitrogen \# 65-0865-14) according to manufacturer\'s instructions. Briefly, cells were incubated with Fixable Viability Dye eFluor™ 780 (1:2,000) at 4°C for 20 min. Subsequently, cells were washed and analyzed by flow cytometry. The following primary monoclonal antibodies (mAbs) were used to determine the maturation state of the DCs: anti--CD80- APC, anti--CD40-APC (all BD Bioscience, San Jose, CA). Measurements were performed on FACSVerse flowcytometers (BD).

Metabolism Assays
-----------------

An XF-96 Extracellular Flux Analyzer (Seahorse Bioscience) was used for Extracellular flux analyses of Dcss (50,000 cells/well) ([@B32]). For mitochondrial fitness tests, OCR was measured sequentially at basal, and following the addition of 1 μM oligomycin, 3 μM FCCP (fluorocarbonyl cyanide phenylhydrazone), 1 μM ROT+1 μM AA. Fatty acid oxidation was determined by monitoring the OCR of cells by using a FAO inhibitor, etomoxir (40 μM) in substrate limited medium. FAO was quantified as a response to etomoxir treatment as previously described ([@B33], [@B34]). For the glycolysis stress test, ECAR was measured sequentially at basal, and following the addition of 10 mM glucose, 1 μM oligolmycin and 50 mM 2-DG. Intracellular concentrations of Branched Chain Amino Acid (BCAA) were measured using colorimetric BCAA Assay Kit (\#MET-5056, Cell Biolabs), as per manufacturer\'s instructions. Contribution of OXPHOS and glycolysis to ATP production was calculated as previously described ([@B35]).

Quantitative Real-Time PCR (qPCR)
---------------------------------

qPCR was carried out in a 25-μl reaction mixture containing 2 μl of cDNA, 12.5 μl of SYBR Green master mix (Applied Biosystems \#A25742, Austin, USA), and 250 nmol of forward and reverse primer. The reaction conditions were as follows: 50°C for 2 min, 95°C for 10 min, and then 40 cycles of 95°C for 15 s and 60°C for 1 min. For qPCR, the primer sequences used are listed in [Supplementary Table 1](#SM1){ref-type="supplementary-material"}.

Cellular ATP Measurements
-------------------------

The levels of ATP were assessed using ATP Bioluminecence Assay Kit CLS II (\#11699695001, Roche GmbH, Mannheim, Germany), according to the manufacturer\'s protocol.

Western Blot Antibodies and Detection
-------------------------------------

The PVDF membrane was probed with rabbit anti-PINK1 (\#6946P; Cell Signaling), rabbit anti- Phospho (S293) BCKDE1A (\#BET A304-672A-M; Bethyl Laboratories), anti-BCKDE1A (H-5) (\#sc-271538; Santa Cruz Biotechnology) and mouse β-actin (\#A5541; Sigma-Aldrich), followed by goat-anti-mouse or goat-anti-rabbit labeled with IRDye infrared dyes (LI-COR Biosciences, Leusden, Netherlands). A LI-COR Odyssey CLX infrared imaging system (LI-COR) was used for fluorescence detection.

Statistical Analysis
--------------------

Comparisons for two groups were calculated using unpaired 2-tailed Student *t*-tests with Microsoft Excel. A 2-way ANOVA with a Bonferroni post-test was used for comparison of more than two groups using GraphPad Prism 6 software (GraphPad). Differences were considered significant at *P* \< 0.05.

Results {#s3}
=======

TLR Agonists Differentially Engage Metabolic Pathways in Human Dendritic Cells (DC)
-----------------------------------------------------------------------------------

To study metabolic adaptations, human DC were stimulated with TLR7/8 ligand pRNA in a time-dependent manner. pRNA stimulation of DC increased oxygen consumption rate (OCR) after 1, 6, and 12 h of stimulation but decreased OCR after 24 h of stimulation ([Figures 1A,B](#F1){ref-type="fig"}). Analysis of extracellular acidification rate (ECAR) revealed that pRNA stimulation increased glycolysis after 1 and 6 h but not after 12 and 24 h of stimulation ([Figure 1C](#F1){ref-type="fig"}). Given the maximum increase in OCR and absence of glycolysis at 12 h after pRNA stimulation, 12 h time point was chosen for further experiments. Next, DCs were stimulated with three different TLR ligands for 12 h. LPS (TLR4), R848 (TLR8), and pRNA (TLR7/8). LPS stimulation of DCs decreased basal OCR, spare respiratory capacity SRC ([Figures 1D,E](#F1){ref-type="fig"}), and ATP-linked respiration ([Supplementary Figure 1A](#SM3){ref-type="supplementary-material"}). This indicates induction of glycolysis which was underscored by the increase of ECAR ([Figure 1F](#F1){ref-type="fig"}) upon LPS stimulation. In contrast, pRNA and R848 stimulation of DCs increased basal OCR, SRC ([Figures 1D,E](#F1){ref-type="fig"}), and ATP-linked respiration indicating upregulation of OXPHOS ([Supplementary Figure 1A](#SM3){ref-type="supplementary-material"}). pRNA and R848 stimulation did not increase glycolysis, as ECAR did not change ([Figure 1F](#F1){ref-type="fig"}). Furthermore, no increase in 2-NBDG uptake was observed in pRNA-stimulated DC ([Supplementary Figure 1B](#SM3){ref-type="supplementary-material"}) also demonstrating the absence of glycolysis induction.

![TLR ligands induced metabolic changes in DC. **(A)** Mitochondrial fitness test of DCs stimulated with pRNA for indicated time points. Data represents mean ± SEM of three independent experiments. **(B,C)** Data was collected within same experiments as **(A)**, but is shown separately for better understanding. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01 (two-way ANOVA). **(D)** Mitochondrial fitness test of DCs stimulated with LPS (100 ng/mL), pRNA and R848 (1 μg/ml) for 12 h. Data represents mean ± SEM of three independent experiments performed in triplicate. **(E,F)** Data was collected within same experiments as **(D)**, but is shown separately for better understanding. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01 (two-way ANOVA).](fimmu-10-02386-g0001){#F1}

The absence of glycolysis induction and the upregulation of OXPHOS in pRNA-stimulated DCs led to the question of whether OXPHOS is required for proper maturation of DCs. Upon activation, immature DCs undergo maturation which is crucial for effective antigen presentation and initiation of the primary immune response. Maturation of DCs is characterized by the high expression of antigen-presenting and costimulatory molecules and the production of pro-inflammatory cytokines. Here, the secretion of pro-inflammatory cytokine TNFα and IFNα and membrane expression of costimulatory molecules CD40 and CD80 was assessed. Inhibiting OXPHOS by Rotenone (ROT) or Antimycin A (AA) significantly reduced both the secretion of TNFα and IFNα ([Figures 2A,B](#F2){ref-type="fig"}) and the upregulation of CD40 and CD80 on pRNA-stimulated DC ([Figures 2C,D](#F2){ref-type="fig"}). pRNA alone or in combination with ROT and AA did not affect cell viability ([Supplementary Figure 1C](#SM3){ref-type="supplementary-material"}). ROT or AA did not affect TNFα secretion ([Figure 2E](#F2){ref-type="fig"}) and upregulation of CD40 and CD80 on LPS-stimulated DC ([Figures 2F,G](#F2){ref-type="fig"}). Collectively, these data indicate pRNA-stimulated DC maturation requires OXPHOS but not glycolysis.

![pRNA stimulation-induced OXPHOS is required for DC maturation. **(A)** TNFα levels on protein level were measured in the supernatant of the DCs stimulated with pRNA for 12 h in the presence or absence of 10 nM rotenone or 10 nM antimycin A. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001 (Student\'s *t*-test). **(B)** IFNα levels on protein level were measured in the supernatant of the DCs stimulated for 12 h with pRNA in the presence or absence of 10 nM rotenone or 10 nM antimycin A. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001 (Student\'s *t*-test). **(C)** Mean fluorescence intensity of CD80 in DCs stimulated for 12 h with pRNA in the presence or absence of 10 nM rotenone or 10 nM antimycin A. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001 (Student\'s *t*-test). **(D)** Mean fluorescence intensity of CD40 in DCs stimulated for 12 h with pRNA in the presence or absence of 10 nM rotenone or 10 nM antimycin A. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01 (Student\'s *t*-test). **(E)** TNFα levels on protein level were measured in the supernatant of the DCs stimulated with LPS (100 ng/mL) for 12 h in the presence or absence of 10 nM rotenone or 10 nM antimycin A. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01 (Student\'s *t*-test) **(F)** Expression of CD80 on DCs stimulated with LPS (100 ng/mL) for 12 h in the presence or absence of 10 nM rotenone or 10 nM antimycin A. One experiment of 3 is shown. **(G)** Expression of CD40 on DCs stimulated with LPS (100 ng/mL) for 12 h in the presence or absence of 10 nM rotenone or 10 nM antimycin A. One experiment of 3 is shown.](fimmu-10-02386-g0002){#F2}

pRNA-Induced Dendritic Cell Maturation Requires Fatty Acid Oxidation (FAO)
--------------------------------------------------------------------------

To unravel the mechanism driving OXPHOS-mediated DC maturation after pRNA stimulation, *NdufA10* and *Pgc1*α gene expression was determined. Peroxisome proliferator-activated receptor gamma co-activator 1-alpha (PGC1α) controls mitochondrial biogenesis ([@B36]--[@B38]). NdufA10 protein is a subunit of OXPHOS complex I ([@B39]). pRNA stimulation of DCs significantly increased *Pgc1*α and *NdufA10* expression, pointing to an increased mitochondrial biogenesis and OXPHOS activity ([Figure 3A](#F3){ref-type="fig"}). Indeed, pRNA stimulation significantly increased mitochondrial content in DC ([Figure 3F](#F3){ref-type="fig"}).

![PINK1 is required for OXPHOS in pRNA-stimulated DC. **(A)** Relative mRNA levels were analyzed after 12 h of pRNA stimulation by (qPCR) and normalized to β-actin expression by using the 2^ΔΔ*CT*^ method. Data represents Mean ± SEM of three independent experiments performed in triplicate. ^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01 (two-way ANOVA). **(B)** DCs transfected with a control siRNA (siCTRL) and pool of two PINK1-targeting siRNAs. Expression of PINK1 was determined by western blotting. β-actin was used as a loading control. **(C)** *PINK1* mRNA levels were analyzed by qPCR and normalized to β-actin expression by using the 2^ΔΔ*CT*^ method. Data represents Mean ± SEM of three independent experiments performed in triplicate. ^\*^*p* \< 0.05 (Student\'s *t*-test). **(D,E)** mRNA levels were analyzed after 12 h of pRNA stimulation by (qPCR) and normalized to β-actin expression by using the 2^ΔΔ*CT*^ method. Data represents Mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001 (Student\'s *t*-test). **(F)** Mean fluorescence intensity of DCs stained with MitoTracker Green^FM^ after 12 h of pRNA stimulation. Data represents Mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01 (Student\'s *t*-test). **(G)** Mitochondrial fitness test of DCs stimulated with pRNA for 12 h. Data represents mean ± SEM of three independent experiments performed in triplicate. **(H)** Data was collected within same experiments as **(G)**, but is shown separately for better understanding. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001 (Student\'s *t*-test).](fimmu-10-02386-g0003){#F3}

A critical regulator of OXPHOS and mitochondrial homeostasis is PINK1 ([@B40]--[@B42]). Effective silencing of PINK1 with siRNA ([Figures 3B,C](#F3){ref-type="fig"}) significantly reduced *Pgc1*α ([Figure 3D](#F3){ref-type="fig"}) and *NdufA10* in pRNA-stimulated DC ([Figure 3E](#F3){ref-type="fig"}). As expected, based on the decrease of *Pgc1*α, the mitochondrial content was lower in PINK1 deficient- compared to PINK1 proficient-DC ([Figure 3F](#F3){ref-type="fig"}). Furthermore, the mitochondrial stress test showed that PINK1-silencing significantly reduced basal OCR, SRC ([Figures 3G,H](#F3){ref-type="fig"}), and ATP-linked OCR ([Supplementary Figure 1D](#SM3){ref-type="supplementary-material"}) in both unstimulated- and pRNA-stimulated DC. Together, these findings indicate that PINK1 is required for pRNA-induced OXPHOS in DC maturation.

To determine how OXPHOS is increased in pRNA-stimulated DC we investigated the involvement of FAO. Previously, FAO-supplemented OXPHOS was shown in TLR9 stimulated plasmacytoid DCs (pDCs) ([@B43]). Here, we show that pRNA stimulation significantly increased expression of *Cpt1*α, *Hadh*α and *Hsl* in DC ([Figure 4A](#F4){ref-type="fig"}). These genes encode enzymes for FAO regulation. A significant increase in FAO was observed in pRNA-stimulated DC ([Figures 4B,C](#F4){ref-type="fig"}; [Supplementary Figure 1E](#SM3){ref-type="supplementary-material"}). PINK1 silencing reduced FAO in both unstimulated- and pRNA-stimulated DC ([Figures 4B,C](#F4){ref-type="fig"}; [Supplementary Figure 1E](#SM3){ref-type="supplementary-material"}). Collectively, these data indicate that FAO is involved in OXPHOS increase in pRNA-stimulated DC.

![pRNA-stimulated DC maturation requires PINK1-dependent FAO. **(A)** Relative mRNA levels were analyzed after 12 h of pRNA stimulation by (qPCR) and normalized to β-actin expression by using the 2^ΔΔ*CT*^ method. Data represents Mean ± SEM of three independent experiments performed in triplicate. ^\*\*\*^*p* \< 0.001 (two-way ANOVA). **(B)** OCR was measured in DCs cultured in substrate-limited medium to indicate oxidation of endogenous fatty acids. Quantification of total FAO as the difference between conditions with or without Etomoxir treatment is shown. Data represents mean ± SEM of three independent experiments two-way ANOVA. **(C)** Data was collected within same experiments as **(B)**, but is shown separately for better understanding. Data represents mean ± SEM of three independent experiments two-way ANOVA. ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001 (Student\'s *t*-test). **(D)** TNFα levels on protein level were measured in the supernatant of the DCs stimulated with pRNA for 12 h. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*\*\*^*p* \< 0.001 (Student\'s *t*-test). **(E)** IFNα levels on protein level were measured in the supernatant of the DCs stimulated with pRNA for 12 h. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001 (Student\'s *t*-test). **(F)** Mean fluorescence intensity of CD80 in DCs stimulated for 12 h with pRNA. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001 (Student\'s *t*-test). **(G)** Mean fluorescence intensity of CD40 in DCs stimulated for 12 h with pRNA. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01; (Student\'s *t*-test). **(H)** TNFα levels on protein level were measured in the supernatant of the DCs stimulated with LPS (100 ng/mL) for 12 h. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01 (Student\'s *t*-test). **(I)** Expression of CD80 on DCs stimulated with LPS (100 ng/mL) for 12 h. One experiment of 3 is shown. **(J)** Expression of CD40 on DCs stimulated with LPS (100 ng/mL) for 12 h. One experiment of 3 is shown.](fimmu-10-02386-g0004){#F4}

To investigate whether pRNA-stimulated DC maturation requires PINK1 regulated metabolic changes, the secretion of pro-inflammatory cytokine TNFα and IFNα and membrane expression of costimulatory molecules CD40 and CD80 were assessed. Upon pRNA stimulation, PINK1 knockdown DC were viable (cell viability over 97%, [Supplementary Figure 2A](#SM4){ref-type="supplementary-material"}) but produced significantly less TNFα and IFNα compared to PINK1 proficient cells ([Figures 4D,E](#F4){ref-type="fig"}). Moreover, increased expression of CD40 and CD80 following pRNA stimulation was also significantly inhibited by PINK1 knockdown ([Figures 4F,G](#F4){ref-type="fig"}). However, PINK1 knockdown did not affect LPS stimulated TNFα secretion ([Figure 4H](#F4){ref-type="fig"}) or expression of CD80 and CD40 ([Figures 4I,J](#F4){ref-type="fig"}). Together, this indicates that pRNA-mediated DC maturation is dependent on PINK1-regulated FAO.

PINK1-Mediated Phosphorylation of BCKDE1α Is Required for pRNA-Induced Maturation of Dendritic Cells
----------------------------------------------------------------------------------------------------

pRNA-mediated TLR stimulation promotes FAO in DCs. *Pgc1*α expression and FAO is increased by BCAA in myotubes ([@B44]). We hypothesize that TLR stimulation increases BCAA levels in DCs, leading to enhanced FAO. Indeed, pRNA stimulation significantly increased BCAA levels in DC ([Figure 5A](#F5){ref-type="fig"}). The homeostasis of BCAA is critically regulated by branched-chain α-ketoacid dehydrogenase (BCKDH) complex, which oxidatively decarboxylates branch-chain α-ketoacids (BCKA) from BCAA. BCKDH is regulated by phosphorylation and dephosphorylation events. BCKDH kinase inactivates the complex by phosphorylation of the E1α subunit of the complex, while BCKDH phosphatase activates the complex by dephosphorylation of E1α. BCKDH kinase is crucial in the regulation of BCKDH activity ([@B45]). Modulation of BCKDH kinase activity changes BCAA homeostasis. 3,6-Dichloro-benzo\[b\]thiophene-2-carboxylic acid (BT2) is an inhibitor of BCKDH kinase ([@B46]). Here, inhibitor BT2 significantly reduced basal and pRNA stimulation-induced BCAA levels in DCs ([Figure 5A](#F5){ref-type="fig"}), indicating involvement of BCKDH kinase. Importantly, BT2 significantly reduced pRNA-stimulated FAO in DC ([Figures 5B,C](#F5){ref-type="fig"}; [Supplementary Figure 1F](#SM3){ref-type="supplementary-material"}).

![PINK1 regulated BCAAs induce FAO in pRNA-stimulated DC. **(A)** Total BCAA concentrations were measured in the DCs stimulated for 12 h with pRNA in the presence or absence of 50 μM BT2, using a colorimetric assay kit. Data represents Mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001 (Student\'s *t*-test). **(B)** OCR was measured in DC cultured in substrate-limited medium in the presence or absence of 50 μM BT2. Quantification of total FAO as the difference between conditions with or without Etomoxir treatment is shown. Data represents mean ± SEM of three independent experiments performed in triplicate. **(C)** Data was collected within same experiments as **(B)**, but is shown separately for better understanding. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001 (Student\'s *t*-test). **(D)** Protein levels of phosphorylated p-BCKDE1α and total BCKDE1α in DCs stimulated for 12 h with pRNA under indicated conditions. β-actin was used as a loading control. **(E)** Total BCAA concentrations were measured in siControl or siPINK1 transfected DCs using a colorimetric assay kit. Data represents Mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001 (Student\'s *t*-test). **(F)** TNFα levels on protein level were measured in the supernatant of the DCs stimulated for 12 h with pRNA in the presence or absence of 50 μM BT2. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*\*\*^*p* \< 0.001 (Student\'s *t*-test). **(G)** IFNα levels on protein level were measured in the supernatant of the DCs stimulated for 12 h with pRNA in the presence or absence of 50 μM BT2. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*\*\*^*p* \< 0.001 (Student\'s *t*-test). **(H)** Mean fluorescence intensity of CD80 in DCs stimulated for 12 h with pRNA in the presence or absence of 50 μM BT2. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001 (Student\'s *t*-test). **(I)** Mean fluorescence intensity of CD40 in DCs stimulated for 12 h with pRNA in the presence or absence of 50 μM BT2. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01 (Student\'s *t*-test).](fimmu-10-02386-g0005){#F5}

We here show that PINK1-dependent FAO requires BCAA. PINK1 phosphorylates several proteins ([@B11], [@B40], [@B47]--[@B50]) and might therefore also regulate BCKDH. Indeed, pRNA stimulation increased phopshorylation of BCKDH subunit BCKDE1α in DCs, which could be inhibited by BCKDH kinase inhibitor BT2 ([Figure 5D](#F5){ref-type="fig"}). Knockdown of PINK1 or addition of BT2 reduced phopshorylation of BCKDE1α, and thereby the BCAA levels were diminished in DCs and no increase was observed after pRNA stimulation ([Figure 5D](#F5){ref-type="fig"}). Knockdown of PINK1 or addition of BT2 reduced TNFα and IFNα production and expression of CD40 and CD80 by pRNA-stimulated DCs ([Figures 4D--G](#F4){ref-type="fig"}, [5E--I](#F5){ref-type="fig"}). Collectively, these data show that DC maturation requires kinase activity of PINK1 for BCKDE1α phosphorylation. Phosphorylation of BCKDE1α disrupts BCAA catabolism and thereby promotes FAO, resulting in maturation of DC after pRNA stimulation.

PINK1 Kinase Activity Determines Immune Stimulatory Capacity of Human DC
------------------------------------------------------------------------

Various factors can transform immune-stimulatory DCs into immune-suppressive DCs, characterized by low expression of co-stimulatory molecules and altered cytokine production ([@B51]). Here, we generated immunosuppressive DCs by adding dexamethasone during culture (Dexa-DC). Indeed, the expression of co-stimulatory molecules i.e., CD40 and CD80 and the production of TNFα was low in Dexa-DC and this could not be increased by pRNA stimulation ([Figures 6D,E](#F6){ref-type="fig"}; [Supplementary Figure 1H](#SM3){ref-type="supplementary-material"}). Moreover, Dexa-DC had lower PINK1 expression ([Figure 6A](#F6){ref-type="fig"}) and lower levels of BCAA compared to DCs ([Figure 6B](#F6){ref-type="fig"}). Kinetin, a membrane permeable precursor of ATP analog N^6^ furfuryl ATP (KTP), increases kinase activity of PINK1 ([@B52]). Here, kinetin significantly increased BCAA levels and CD40 expression but not CD80 expression in Dexa-DCs ([Figures 6B,D,E](#F6){ref-type="fig"}). pRNA in combination with kinetin significantly increased CD40 and CD80 expression and the production of TNFα in Dexa-DC ([Figures 6C--E](#F6){ref-type="fig"}). Together, these data show that an increase in PINK1 kinase activity restored the immune- stimulatory capacity of immune-suppressive Dexa-DC.

![Kinetin primes immunosuppressive DC for maturation. **(A)** Expression of PINK1 in DCs was determined by western blotting. β-actin was used as a loading control. **(B)** Total BCAA concentrations were measured in DCs, stimulated for 12 h with pRNA in the presence or absence of 20 μM kinetin, using a colorimetric assay kit. Data represents Mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01 (Student\'s *t*-test). **(C)** TNFα levels on protein level were measured in the supernatant of the DCs stimulated for 12 h with pRNA in the presence or absence of 20 μM kinetin. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01 (Student\'s *t*-test). **(D)** Mean fluorescence intensity of CD80 in DCs stimulated for 12 h with pRNA in the presence or absence of 20 μM kinetin. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01 (Student\'s *t*-test). **(E)** Mean fluorescence intensity of CD40 in DCs stimulated for 12 h with pRNA in the presence or absence of 20 μM kinetin. Data represents mean ± SEM of three independent experiments performed in triplicate. ^\*\*^*p* \< 0.01 (Student\'s *t*-test). **(F)** Mechanistic model of OXPHOS-mediated DC activation. Activation of TLR7/8 with pRNA lead to increase in OXPHOS. pRNA stimulation phosphorylates BCKDE1α in a PINK1-dependent manner. pRNA stimulation increased branched-chain amino acid (BCAA) to promote FAO. Increased FAO and OXPHOS were required for DC activation.](fimmu-10-02386-g0006){#F6}

Discussion {#s4}
==========

Pathogen recognition by antigen presenting cells to initiate immune responses is a key process in host defense. For *in vitro* studies, TLR4 ligand LPS is most commonly used to mimic inflammatory responses. LPS promotes metabolic rewiring resembling the Warburg effect in both DCs and bone marrow-derived macrophages (BMDMs) ([@B53], [@B54]). While knowledge concerning molecular pathways controlling metabolic routes in DC is accumulating ([@B55]), the specificity of metabolic adaptations after stimulation with different TLR ligands is not studied in detail. Here, we demonstrate that stimulation of DC via TLR7/8 engages a different metabolic pathway than DC stimulated *via* TLR4. We here confirm previous results concerning LPS stimulation of DC resulting in a switch to glycolysis for maturation. In contrast, TLR7/8 stimulated DC increase OXPHOS concurrently with glycolysis. However, this glycolysis diminishes after 12 h while increased OXPHOS is maintained. A recent study demonstrated that different DC subtypes, i.e., human pDCs and monocyte-derived DCs (moDCs), have distinct metabolic requirements for maturation. Upon stimulation of RIG-I, moDC increase glycolysis whereas pDCSs employ OXPHOS ([@B56]). Previously, we reported that human blood-derived DCs i.e., cDC2^+^ mDC and pDC for maturation switch to glycolysis and OXPHOS, respectively ([@B25]). This underlines the distinct metabolic adaptations triggered by different pathogens depending on their specific TLR binding.

Specific stimulation of DC via TLR7/8 by pRNA increased OXPHOS accompanied by an increased mitochondrial content. A critical regulator of OXPHOS and mitochondrial homeostasis is PINK1. Indeed, PINK1 knockdown reduced the pRNA-induced increase of OXPHOS and mitochondrial content. PINK1 is also involved in mitophagy and has a role in MHC antigen presentation ([@B57]--[@B59]). Lack of accumulation of mitochondrial content in PINK1 deficient cells upon pRNA stimulation indicates absence of mitophagy in our model ([@B60]). Albeit, our data show that PINK1 is crucial for pRNA-stimulated DC maturation, indicating a mitophagy-independent function of PINK1. Previously, PINK1 is described to be crucial for survival ([@B61], [@B62]). However, the viability of PINK1 knockdown DC was not affected either in the presence nor absence of pRNA ([Supplementary Information](#SM2){ref-type="supplementary-material"}). Furthermore, it is shown that PINK1 deficiency results in less ATP due to impaired mitochondrial fission leading to defective assembly of the ETC complexes, and reduction in mitochondrial respiration and mitochondrial buffering capacity ([@B63]--[@B66]). Total intracellular ATP levels were increased in both pRNA maturation of DC and PINK1-knockdown DC ([Supplementary Information](#SM2){ref-type="supplementary-material"}). We here show that PINK1 knockdown DC maintain cell viability by reprogramming bioenergetics from OXPHOS to glycolysis ([Supplementary Information](#SM2){ref-type="supplementary-material"}). Loss of PINK1 has been reported to result in stabilization of HIF1α which stimulates glycolysis ([@B67]). Indeed, glucose uptake was increased in PINK1-deficient cells and further increased by pRNA stimulation ([Supplementary Information](#SM2){ref-type="supplementary-material"}). Intriguingly, *Glut1* levels did not change upon pRNA stimulation, however loss of PINK1 increased *Glut1* levels, which has been reported to be involved in glucose uptake in DCs ([@B68]). These data suggest that loss of PINK1 reprograms glucose metabolism ([Supplementary Information](#SM2){ref-type="supplementary-material"}), possibly through HIF1α, in DCs to sustain cell viability.

We here identified PINK1 as a novel regulator of BCAAs, which are important for FAO to supplement OXPHOS crucial for TLR7/8-induced DC maturation. The activity of BCKDH complex is regulated *via* phosphorylation/dephosphorylation of BCKDE1α. Previously, PINK1 is shown to be able to phosphorylate target proteins in a kinase-dependent manner ([@B11], [@B40], [@B47]--[@B50], [@B69]). Our data show that PINK1 regulates phosphorylation of BCKDE1α in DCs and thus is a critical regulator of BCKDH complex for BCAA catabolism. Interestingly, Parkinson disease patients, who have mutated PINK1 in neurons ([@B64]), have decreased BCAA serum levels associated with an increase in the clinical severity of the disease ([@B70]). Therefore, our finding that PINK1 regulates BCAA catabolism may have important implications for patients suffering from Parkinson disease. TLR7/8 stimulation with pRNA increased BCAA promoting FAO in DC. Similarly, for pDC maturation, TLR9 agonist, CpG-A, also enhanced FAO ([@B43]). In contrast, FAO is not necessary for maturation of mouse bone marrow-derived DCs stimulated with LPS ([@B7]). Collectively, DCs engage distinct metabolic routes for maturation upon stimulation *via* different TLRs.

Our data identified PINK1 as a critical regulator of BCAA catabolism, whereas previously PINK1 is shown to critically regulate FAO ([@B71]). This led to the question of whether PINK1 *via* BCAAs contribute to FAO. We observed that PINK1 knockdown reduced pRNA-induced FAO in DCs. BCAAs are required for fatty acid synthesis ([@B72]) and promote FAO in muscles and myotubes ([@B44], [@B73]). Consistently, inhibition of BCAAs levels abrogated pRNA-induced FAO in DC. BCAA leucine increases expression of *Cpt1, Cpt2* ([@B74]), *PPAR***γ** ([@B75]), *Pgc1*α, and *Nrf-1* ([@B76]). Indeed, *Pgc1*α expression and mitochondrial content were increased after pRNA stimulation of DC, hinting at increased FAO. Another possible mechanism for BCAA-mediated FAO is that leucine increases SIRT1 activity, which in turn phosphorylates AMPK ([@B76]). AMPK subsequently regulates FAO through phosphorylation of acetyl-CoA carboxylase 2 ([@B77]). Given the increase in BCAA after TLR7/8 stimulation of DC by pRNA it seems likely that SIRT1-phospho AMPK increases FAO. An alternative mechanism for BCAA-mediated FAO could be that leucine inhibits mTOR ([@B78]), which is central to lipid homoeostasis and mTOR inhibition increases FAO ([@B79]). Therefore, it is possible that pRNA stimulation of DC increased BCAA and thereby inhibited mTOR resulting in FAO.

In immunosuppressive DC (Dexa-DC), PINK1 levels were diminished and increasing PINK1 kinase activity directed the immunosuppressive phenotype toward an immunostimulatory phenotype. Previously, Ibrahim et al. showed that DC with lower lipid content are immunosuppressive ([@B80]). PINK1 expression is indeed necessary for regulating lipid droplet formation and mitochondrial FAO ([@B81]). Activation of DC induces fatty acid synthesis, which results in increased lipid storage in lipid droplets ([@B82]). Together, these reports suggest that lower PINK1 levels likely result in reduced fatty acid synthesis and lipid storage in immunosuppressive DC. Induction of PINK1 kinase activity likely increased fatty acid synthesis *via* BCAAs in immunosuppressive DC, which was then utilized for FAO upon TLR7/8 stimulation. The observation that PINK1 levels were lower in immunosuppressive DC is in contrast with the observed effects in Parkinson patients and *Pink1*^−/−^ mice. There, high levels of TNF-α, IFN-γ, and IL-6 are all indicative of an inflammatory phenotype that are observed ([@B83], [@B84]). This can be due to reduced OXPHOS activity, mitophagy induction, and higher oxidized mtDNA, acting as an inflammatory signal in the Parkinson model ([@B84], [@B85]). Here, we observed an increase in OXPHOS activity and did not observe mitophagy possibly explaining the immune suppressive phenotype.

Our data, together with recent reports, show that distinct metabolic programs in DCs can be induced dependent on the stimulus. Manipulation of human DC functionality via metabolic programming needs a broader understanding, especially since the diversity of responses induced by different PRRs is very broad. We identified the PINK1-BCAAs axis as a novel metabolic programming pathway in DCs ([Figure 6F](#F6){ref-type="fig"}), hence, strategies aiming at modifying this axis might provide a clinical benefit in immune-related pathologies.
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